Eltrombopag for the treatment of immune thrombocytopenia

Expert Review of Hematology

Volumn 4, Issue 3, 2011, Pages 261-269

  Cheng, Gregory ^a  

^a 9/F ICBC Tower   (China)

Author keywords

eltrombopag; immune thrombocytopenia; thrombopoietin receptor agonist

Indexed keywords

ELTROMBOPAG; PLACEBO; ROMIPLOSTIM; THROMBOCYTE ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; ECCHYMOSIS; EPISTAXIS; HEADACHE; HEART INFARCTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSOMNIA; MEGAKARYOPOIESIS; MORBIDITY; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; THROMBOEMBOLISM; VOMITING;

BENZOIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDRAZINES; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOPENIA;

EID: 79959200936     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.25     Document Type: Article

References (35)

1. Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an International Working Group. Blood 113, 2386-2393 (2008)
2. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol. Oncol. Clin. North Am. 21, 743-759 (2007)
3. Cohen YC, Djulbegovic B, Shamai- Lubovitz O et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Intern. Med. 160, 1630-1638 (2000)
4. Portielje JE, Westendorp RG, Kluin- Nelemans HC et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97, 2549-2554 (2001)
5. Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115, 168-186 (2010)
6. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP)Blood 106, 2244-2251 (2005)
7. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N. Engl. J. Med. 346, 995-1008 (2002)
8. Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr. Opin. Hematol. 14, 535-556 (2007)
9. Hoffman R, Zaknoen S, Yang HH et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N. Engl. J. Med. 312, 1170-1174 (1985)
10. Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 102, 887-895 (2003)
11. Houwerzijl EJ, Blom NR, van der Want JJ et al. Ultrastructural study shows morphologic features of apoptosis and parαapoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 103, 500-506 (2004)
12. McMillan R, Wang L, Tomer A et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 103, 1364-1369 (2004)
13. Zhao YQ, Wang QY, Zhai M et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi 43, 608-610 (2004)
14. Nomura S, Dan K, Hotta T et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100, 728-730 (2002)
15. Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98, 3241-3248 (2001)
16. Basser RL, O Flaherty E, Green M et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99, 2599-2602 (2002)
17. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther. 76, 628-638 (2004)
18. Erickson-Miller CL, DeLorme E, Tian SS et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol. 33, 85-93 (2005)
19. Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood 104, 59b (2004) (Abstract 3888)
20. Jenkins JM, Williams D, Deng Y et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109, 4739-4741 (2007)
21. Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 371, 395-403 (2008)
22. Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 357, 2237-2247 (2007)
23. Bussel JB, Provan D, Shamsi T et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373, 641-648 (2009)
24. Bussel J, Psaila B, Saleh M et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood 112, 1176 (2008) (Abstract 3431)
25. Cheng G, Saleh M, Marcher C et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized Phase 3 study. Lancet 377, 393-402 (2011)
26. Saleh M, Cheng G, Bussel J et al. EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010. Blood 166, 36 (2010) (Abstract 67)
27. Sarpatwari A, Bennett D, Logie JW et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 95, 1167-1175 (2010)
28. Douglas V, Tallman M, Cripe L et al. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am. J. Clin. Pathol. 117, 844-850 (2002)
29. Bussel J, Kuter D, Pullarkat V et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113, 2161-2171 (2009)
30. Mazzucconi MG, Fazi P, Bernasconi S et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 109, 1401-1407 (2007)
31. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104, 2623-2634 (2004)
32. Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter Phase 2 study. Blood 112, 999-1004 (2008)
33. Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med. 146, 25-33 (2007)
34. Kantarjian H, Fenaux P, Sekeres MA et al. Safety and efficacy of romiplostim in patients with lower risk myelodysplastic syndrome and thrombocytopenia. J. Clin. Oncol. 28, 437-444 (2010)
35. McHutchison JG, Dusheiko G, Shiffman ML et al. Eltrombopag for thrombocytopenia in patients with cirrhosisassociate hepatitis C. N. Engl. J. Med. 357, 227-236 (2007).